Cinacalcet Tablets recalled over manufacturing violations
- Recall date
- November 7, 2024
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Aurobindo Pharma USA Inc recalls Cinacalcet Tablets, 60mg, packaged in: a) 30-count HDPE bottle (NDC 65862-832-30), b) 500-count HDPE bottle (NDC 65862-…
- Recall number
- D-0078-2025
- FDA classification
- Class II
- Brand / firm
- Aurobindo Pharma USA Inc
- Sold / distributed
- USA Nationwide
Why it was recalled
cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Cinacalcet Tablets, 60mg, packaged in: a) 30-count HDPE bottle (NDC 65862-832-30), b) 500-count HDPE bottle (NDC 65862-832-05), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India.
Get recall alerts
Free email alert whenever Aurobindo Pharma USA Inc has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Aurobindo Pharma USA Inc